<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-149835" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Point-of-Care Testing</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Larkins</surname>
            <given-names>Michael C.</given-names>
          </name>
          <aff>East Carolina University Brody School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thombare</surname>
            <given-names>Aparna</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Larkins declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aparna Thombare declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-149835.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Point-of-Care Testing (POCT) is clinical laboratory testing conducted close to the site of patient care where care or treatment is provided.POCT provides rapid turnaround of test results with the potential to generate a result quickly so that appropriate treatment can be implemented, leading to improved clinical or economic outcomes compared to laboratory testing.
Technological advances, such as miniaturization of electronics and improved instrumentation, have revolutionized POCT, enabling the development of smaller and more accurate devices. POCT can be performed by various healthcare professionals and, in some cases, even by patients themselves. This review explores the methodology, benefits, utilization, and factors that can interfere with POCT, highlighting the importance of an interprofessional team in evaluating and treating patients using POCT. By leveraging the expertise of different healthcare professionals, POCT can be effectively integrated into patient care, leading to improved outcomes and patient satisfaction.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for point-of-care testing based on patient presentation and clinical scenario.</p></list-item><list-item><p>Apply quality control measures and perform regular maintenance and calibration of point-of-care testing equipment to ensure accurate and reliable results.</p></list-item><list-item><p>Implement point-of-care testing procedures following established protocols, including proper specimen collection, handling, and storage.</p></list-item><list-item><p>Collaborate with other healthcare professionals in the interpretation and integration of point-of-care test results into patient management plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149835&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149835">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-149835.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Point-of-Care Testing (POCT) is clinical laboratory testing conducted close to the site of patient care where care or treatment is provided.<xref ref-type="bibr" rid="article-149835.r1">[1]</xref> POCT provides rapid turnaround of test results with the potential to generate a result quickly so that appropriate treatment can be implemented, leading to improved clinical or economic outcomes compared to laboratory testing.<xref ref-type="bibr" rid="article-149835.r2">[2]</xref></p>
        <p>Traditional laboratory testing typically involves a multiple-step process that includes collecting samples from the patient at the bedside or the clinic, transporting them to a centralized laboratory (often located far away), and then subjecting the samples to several processing steps.<xref ref-type="bibr" rid="article-149835.r3">[3]</xref> The delay in treatment caused by the time-consuming traditional laboratory testing&#x000a0;can hinder timely clinical decision-making. POCT&#x000a0;addresses this challenge by bringing the laboratory to the patient. Portable and handheld testing devices enable healthcare workers to perform rapid testing on samples, significantly reducing the time needed for medical decision-making.</p>
        <p>The concept of on-site or near-patient testing for blood analysis was initially explored in England during the 1950s and was referred to as "near-patient testing."<xref ref-type="bibr" rid="article-149835.r4">[4]</xref> In the early 1980s, Dr. Gerald J. Kost introduced the term "point-of-care testing" after extensive research on the application of biosensors for monitoring ionized calcium levels in whole blood.<xref ref-type="bibr" rid="article-149835.r5">[5]</xref> The term "point-of-care testing" was subsequently codified with the definition of "testing at or near the site of patient care."<xref ref-type="bibr" rid="article-149835.r3">[3]</xref></p>
        <p>Technological advances, including the miniaturization of electronics and improved instrumentation, have&#x000a0;facilitated the development of increasingly smaller and more accurate POCT devices.<xref ref-type="bibr" rid="article-149835.r6">[6]</xref> Cutting-edge POCT integrates microneedles and microfluidics for improved comfort, speed, and accuracy.<xref ref-type="bibr" rid="article-149835.r7">[7]</xref><xref ref-type="bibr" rid="article-149835.r8">[8]</xref></p>
        <p>The following features of POCT are ubiquitous:<xref ref-type="bibr" rid="article-149835.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>POCT should be simple to use.</p>
          </list-item>
          <list-item>
            <p>Reagents and consumables should have durable resistance during storage and use.</p>
          </list-item>
          <list-item>
            <p>POCT results should align with established laboratory methods.</p>
          </list-item>
          <list-item>
            <p>POCT should ensure safety during testing.</p>
          </list-item>
        </list>
        <p>Various guidelines, such as the ASSURED Guidelines by the World Health Organization (WHO), exist for specific subsets of POCT, such as sexually transmitted infections (STI).<xref ref-type="bibr" rid="article-149835.r9">[9]</xref> The ASSURED acronym stands for Affordable, Sensitive, Specific, User-friendly, Rapid, Robust, Equipment-free, and Delivered (to the end user), which are key criteria for effective POCT, as proposed by the World Health Organization (WHO). Affordable is for patients at risk of infection,&#x000a0; and equipment-free means no complex equipment is required.&#x000a0;</p>
        <p>The National Academy of Clinical Biochemistry (NACB) has developed evidence-based guidelines for POCT, providing grading and recommendations to optimize the use of POCT based on scientific research and clinical evidence.<xref ref-type="bibr" rid="article-149835.r10">[10]</xref></p>
        <p>POCT guidelines generally emphasize the rapid results and cost-effectiveness of POCT, along with the importance of high sensitivities and specificities to support informed clinical decision-making.</p>
      </sec>
      <sec id="article-149835.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>There are&#x000a0;3 primary stages in the POCT process: pre-analytical, analytical, and post-analytical. The pre-analytical phase occurs before running the POCT on a sample and involves collection, transport, preparation, and loading. The analytical phase is the stage in which the actual testing sequence of a POCT is conducted. The post-analytical phase&#x000a0;begins when testing is complete, and an obtained result is available. During this phase,&#x000a0;the obtained result from the test&#x000a0;is&#x000a0;communicated for treatment&#x000a0;through the electronic medical record (EMR) or written or verbal instructions directly to the treatment team.&#x000a0;The post-analytical step is also when "so-called" critical values, which are values that deviate significantly from normal reference values and indicate a pathological process.&#x000a0;The resultant values are interpreted during this step to guide appropriate actions and interventions.</p>
        <p>Specimen collection and handling are critical components of POCT since testing is performed directly on&#x000a0;the collected specimen.<xref ref-type="bibr" rid="article-149835.r11">[11]</xref> The pre-analytical phase of specimen collection and handling is crucial and represents the most critical controllable variable in POCT. Adhering to personnel regulations, appropriately preparing patient and specimen collection containers (including fixatives or special media), and ensuring compliance with patient and specimen identification requirements are essential for effective collection and handling. Additionally, accurate clinical documentation and proper specimen storage are necessary to maintain the integrity, accuracy, and safety of the testing process.</p>
        <p>Adhering to the manufacturer's instructions for use (MIFU) or package insert is crucial in ensuring accurate testing in POCT. This is particularly important regarding sample preparation, including factors like centrifugation time, and may vary between manufacturers and sample types. Professionals performing POCT should carefully follow the specific instructions provided by the manufacturer for each apparatus used. Professionals prefer some POCT methods that utilize whole blood as they eliminate the need for additional processing steps or centrifugation.&#x000a0;Additionally, sample collection containers&#x000a0;must be within the manufacturer's date stamp to maintain the quality and reliability of the testing process.&#x000a0;</p>
        <p>POCTs&#x000a0;are more susceptible to interfering substances and have&#x000a0;a narrow margin of error&#x000a0;due to smaller sample sizes compared to conventional laboratory tests.</p>
        <p>Proper technique is crucial when drawing samples, particularly when accessing a central line.<xref ref-type="bibr" rid="article-149835.r12">[12]</xref>&#x000a0;This involves flushing the line with heparin and discarding at least twice the volume of the line (2 to 5 mL) before sample collection. It is recommended to wait at least 15 minutes after a blood transfusion before drawing a sample for POCT.</p>
        <p>Samples collected for blood gas analysis are susceptible to changes in oxygen partial pressure. Therefore, it is crucial to maintain anaerobic conditions during sample collection to ensure accurate laboratory values.<xref ref-type="bibr" rid="article-149835.r13">[13]</xref> Controlling factors such as removing all air bubbles from a sample, using a plastic syringe for collection, and the time and temperature of sample storage (if storage is required) before analysis are crucial for accurate blood gas analysis.</p>
      </sec>
      <sec id="article-149835.s4" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>POCT testing devices&#x000a0;are classified based on the testing modality and the test size.<xref ref-type="bibr" rid="article-149835.r9">[9]</xref> Test size in POCT spans a wide range, and ongoing research focuses on miniaturization. Handheld POCT devices, including dipsticks and meters like glucometers, represent smaller-scale options within this spectrum.</p>
        <p>The most recent iterations of these devices feature cartridges that enable multiple tests, including whole blood analysis for cardiac markers, blood gases, and various hematologic and endocrine analytes. On the larger end of this spectrum, there are larger benchtop POCT units that require dedicated space near a patient to qualify as POC.</p>
        <p>Many of these benchtop POCT units are equipped with multiple testing types and modalities, allowing for a wide range of diagnostic tests to be performed within a single device. Common examples of tests performed on benchtop POCT units include hemoglobin A1c, C-reactive protein (CRP), and general chemistry analytes. The demand for smaller and more precise benchtop POCT devices has been a significant catalyst for innovation in reducing the size of these instruments. Advancements in technology and engineering have enabled the development of compact and highly accurate benchtop POCT units.</p>
        <p>
<bold>Testing Strips and Lateral-flow Testing</bold>
</p>
        <p>POCT encompasses a wide range of testing modalities tailored to specific applications. The most basic POCT takes advantage of an interaction between an analyte and a substance, usually impregnated or contained, so that a sample can be added or mixed in a controlled manner.<xref ref-type="bibr" rid="article-149835.r14">[14]</xref>&#x000a0;An example is using test strips (eg, urine test strips). These strips are generally dried, porous matrices with impregnated carrier elements that interact with the analyte(s) when exposed. The interaction between the analyte and the testing reagents often involves a chemical reaction that produces a&#x000a0;color change. This color change can be interpreted as a binary value indicating the presence or absence of the analyte&#x000a0;or as an indication of the analyte concentration using a scale (eg, trace protein, 1+, 2+, 3+).</p>
        <p>A more complex approach to POCT is lateral-flow testing. This type of diagnostic testing utilizes a layer of supporting material, such as porous paper of cellulose fiber filters or woven meshes. The supporting material contains capillary beds to whisk fluid samples to location(s) on the support material with substances that react&#x000a0;with measured analytes in the sample. A&#x000a0;well-known&#x000a0;example is the at-home pregnancy test, which commonly utilizes an immunoassay&#x000a0;to detect the presence of human chorionic gonadotropin (hCG, specifically beta-hCG) in urine.</p>
        <p>Urine is exposed to one end of the supporting material in the test device; capillary beds then move the urine through the supporting material to specific sites that react with beta-hCG. This configuration commonly has&#x000a0;2 lines of reactive material,&#x000a0;one&#x000a0;that serves as the control and another that indicates a binary yes&#x000a0;or no indication. The test is positive if both lines (also known as stripes) appear&#x000a0;or change color and negative if only the control line is visible. Failure of the control line to appear indicates an invalid or&#x000a0;faulty test, which could result from a manufacturing defect, damage, or expired test.</p>
        <p>In many instances, POCTs that utilize simple test strips or lateral-flow testing&#x000a0;provide qualitative or semiquantitative results and&#x000a0;do not provide precise information regarding the specific concentration of the measured analyte.</p>
        <p>
<bold>Immunoassays</bold>
</p>
        <p>POCT&#x000a0;testing that utilizes immunoassays relies on antibodies to bind to a specific target&#x000a0;when the concentration&#x000a0;exceeds a certain threshold.<xref ref-type="bibr" rid="article-149835.r14">[14]</xref> Targets in immunoassays for POCT can encompass a wide range of substances, including proteins, drugs, and pathogens. POCTs are available in various formats, including both individual tests and platforms with multiple built-in tests. In general, testing platforms require more space and greater expertise&#x000a0;and training; this generally scales with the number of tests offered.</p>
        <p>Deciding between using a testing platform versus an individual test or even utilizing an array of individual tests depends on the workflow and throughput required. Higher sample volume can often be accommodated more effectively using a POCT testing platform. However, the suitability of a specific platform depends on the testing type and the platform's capabilities.</p>
        <p>One subset of immunoassays is the direct assay, which provides a straightforward method for detecting an analyte. In a direct immunoassay, the analyte of interest is directly bound by an antibody that specifically recognizes and binds to it. This binding event is then detected, typically through fluorescence, by an optical sensor. The fluorescence signal indicates the presence and quantity of the analyte in the sample.</p>
        <p>In situations where a direct assay is not feasible, competitive immunoassays can be employed. These assays utilize the principle of competitive binding between a measurable, secondary analyte and the target analyte.&#x000a0;As the test antibodies bind to more of the primary analyte, the level of bound, measurable analyte decreases due to competitive binding; this allows for the determination of the primary analyte's concentration. Unlike&#x000a0;simple test strip-based POCT, immunoassay POCT provides quantitative information for specific analytes.<xref ref-type="bibr" rid="article-149835.r15">[15]</xref><xref ref-type="bibr" rid="article-149835.r16">[16]</xref></p>
        <p>
<bold>Antigen-based Testing</bold>
</p>
        <p>POCT, which involves the detection of known antigens or antibodies specific to a particular disease or disease state, has been widely employed as a common practice in healthcare.<xref ref-type="bibr" rid="article-149835.r17">[17]</xref>&#x000a0;Immunoassay-based POCT is commonly used to rapidly detect group A <italic toggle="yes">Streptococcus</italic>, mononucleosis, and influenza A and B. These tests utilize immunoassays that bind specific antigens or antibodies. Immunosay-based POCT offers a fast turnaround time (TAT) but may have lower sensitivities and specificities compared to traditional laboratory and molecular testing methods.</p>
        <p>
<bold>Molecular POCT</bold>
</p>
        <p>The demand for molecular POCT with high sensitivity and specificity and a relatively short turnaround time (although longer than antigen-based testing) spurred its development.<xref ref-type="bibr" rid="article-149835.r17">[17]</xref> This form of testing&#x000a0;detects&#x000a0;DNA or RNA sequences&#x000a0;indicative of&#x000a0;the presence of disease. Nucleic acid amplification testing (NAAT) is used to identify DNA or RNA in small test samples. The nucleic acids of interest are replicated to increase their concentration (ie, amplify them) so they are easier to detect.<xref ref-type="bibr" rid="article-149835.r18">[18]</xref></p>
        <p>There are various forms of this testing, including reverse transcription polymerase chain reaction (RT-PCR)&#x000a0;and isothermal amplification methods such as nicking endonuclease amplification reaction (NEAR) and transcription-mediated amplification (TMA).</p>
        <p>It is important to note that while molecular POCTs often have higher sensitivities and specificities compared to antigen-based POCTs, this is not always the case. Additionally, the increased sensitivity and specificity&#x000a0;provided by this&#x000a0;POCT modality may not always be clinically beneficial, as the detection of an analyte&#x000a0;does not necessarily&#x000a0;correlate with a&#x000a0;specific disease state or the need for treatment (eg,&#x000a0;the presence of a&#x000a0;small amount of <italic toggle="yes">Clostridium difficile</italic>&#x000a0;in a patient's stool does not always&#x000a0;indicate the need for treatment of&#x000a0;a <italic toggle="yes">C difficile</italic> infection.<xref ref-type="bibr" rid="article-149835.r19">[19]</xref></p>
      </sec>
      <sec id="article-149835.s5" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Testing procedures for POCT vary based on the specific manufacturer, test, and sample type. For accurate results in most POCT units, setting up and calibrating&#x000a0;the specific test before use properly is essential. Following the manufacturer's instructions for use (MIFU) or package insert for each POCT apparatus is crucial in achieving accurate testing.</p>
        <p>
<bold>General POCT Testing Procedures</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>A sample is obtained for analysis. This could be a drop of blood for blood glucose concentration via a glucometer or urine for beta-hCG. Various requirements regarding the patient's state, the specimen's state, and the preparation needed for accurate testing exist. This is discussed in further detail in both the "Specimen Requirements and Procedures" and "Quality Control and Lab Safety" sections.<xref ref-type="bibr" rid="article-149835.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>The sample is applied to the POCT device. Immediately before this step, a reagent may facilitate accurate testing. For example, some POCT units for COVID-19 require samples obtained via nasopharyngeal or oropharyngeal swabs to be placed in a reagent solution to facilitate the transfer of antigen into the solution.<xref ref-type="bibr" rid="article-149835.r21">[21]</xref> This allows for the distribution of the antigen throughout the solution and increases test accuracy. In some types of POCT, the sample can be directly applied to the device, which typically includes a disposable cartridge for analyzing the analyte. This disposable cartridge can be disposed of after use, reducing the risk of cross-contamination.</p>
          </list-item>
          <list-item>
            <p>Once the test is performed, the result is obtained and can be directly transferred to the patient's electronic medical records (EMR) if the POCT device is integrated or interfaced with the EMR system.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-149835.s6" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Due to the portable nature of POCT, the reagents, tests, and samples are often exposed to conditions that may differ from those in a traditional laboratory setting. Humidity, temperature, time to testing, and oxygen content can fluctuate more in the POCT setting than in the conventional laboratory environment. Most interfering factors with POCT occur before the test is run (pre-analytical phase).<xref ref-type="bibr" rid="article-149835.r22">[22]</xref></p>
        <p>Errors in the pre-analytical phase can occur during patient identification and in the specimen's identification, collection, handling, processing, transport, and storage. These errors may include hemolysis, clotting, underfilling or overfilling a specimen container, improperly securing specimen containers before transport, prolonged tourniquet time, and changes in the sample concentration (eg, during aliquoting).</p>
        <p>Notably,&#x000a0;the detection of&#x000a0;hemolysis in POCT using whole blood samples (including fingerstick tests) is challenging.<xref ref-type="bibr" rid="article-149835.r23">[23]</xref> Errors during specimen transfer and loading,&#x000a0;such as bubbles, microclots, and gross clotting, can occur, especially if the procedure is not followed appropriately or lacks oversight. Increased time to testing&#x000a0;can interfere with POCT, as&#x000a0;observed in the case of&#x000a0;blood glucose testing in whole blood. Adequate training is a critical component of POCT, as pre-analytical errors have an inverse association with test operator experience.</p>
        <p>Other interfering factors may be directly related to the patient's physical state. For instance, elevated biotin intake (eg, from vitamin supplementation) can interfere with certain immunoassays, such as human immunodeficiency virus (HIV) POCT.<xref ref-type="bibr" rid="article-149835.r24">[24]</xref>&#x000a0;This stems from the interaction between biotin and streptavidin in the assay. Affected assays include but are not limited to pancreatic, prostate, and ovarian cancer POCT and pituitary and thyroid function tests. Reading the MIFU or package insert is essential for POCT, as certain drugs can interfere with the test and affect accuracy. Some POC glucose monitoring systems may&#x000a0;report erroneously elevated glucose levels in patients treated with maltose, icodextrin, galactose, or xylose.<xref ref-type="bibr" rid="article-149835.r25">[25]</xref></p>
        <p>Hemolysis, icterus, and lipemia may result in inaccurate or incalculable results. Potassium measurements are susceptible to this error. Testing in conventional laboratories often includes a step to determine the serum index in addition to testing for a specific analyte.<xref ref-type="bibr" rid="article-149835.r13">[13]</xref></p>
        <p>Collectively, these indices are often referred to as hemoglobin (H), lipemia (L), and icterus (I), or HIL, indices.<xref ref-type="bibr" rid="article-149835.r26">[26]</xref> These are obtained most typically via spectrophotometric assessment. However, in POCT, hemolysis, icterus, and lipemia can only be detected by visual inspection of a centrifuged aliquot of the sample. High turbidity or an excess of an untested component in a sample, such as in whole blood samples with high concentrations of lipids, may also skew test results or result in an error.<xref ref-type="bibr" rid="article-149835.r27">[27]</xref></p>
        <p>Ways to resolve these errors vary based on the devices used and MIFU; in some cases, dilution can resolve sample errors related to excess bilirubin, and ultracentrifugation can help fix errors related to excess lipids. Patients with reduced or compromised peripheral circulation, as seen in patients with sepsis, shock, or diabetic ketoacidosis, may have inadequate capillary blood samples.<xref ref-type="bibr" rid="article-149835.r28">[28]</xref></p>
      </sec>
      <sec id="article-149835.s7" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>
<bold>Results</bold>
</p>
        <p>POCT results that yield critical values are typically acted upon promptly, leading to potential changes in clinical management.<xref ref-type="bibr" rid="article-149835.r29">[29]</xref> This could be as benign as a reflexive beta-hCG taken after a positive urine pregnancy test in the emergency department. Therefore it is essential to record the result and action taken whenever a critical value result is obtained.</p>
        <p>Critical values, unlike urgent or STAT tests, are defined as test results that significantly deviate from the established normal range, irrespective of the patient's condition. STAT or urgent tests are designated as such by the individual ordering the test, and therefore prior knowledge of the patient's status is generally needed.</p>
        <p>
<bold>Reporting Critical Findings</bold>
</p>
        <p>Critical values should be treated as reportable events, even if previous critical values are already known for a particular patient.<xref ref-type="bibr" rid="article-149835.r29">[29]</xref> The critical value reporting policy should be consistently followed for each instance of obtaining a critical value. Deviation from this policy should only be considered in exceptional cases supported by sufficient evidence, such as obvious testing errors or pre-analytical errors, justifying the decision to ignore the critical value.</p>
      </sec>
      <sec id="article-149835.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Because of its quick turnaround time and place in various workflows,&#x000a0;POCT has great clinical significance; the information gleaned from POCT is used routinely to guide patient treatment and management. POCT offers several advantages compared to conventional lab testing, with benefits that vary depending on the specific setting in which the testing is conducted.<xref ref-type="bibr" rid="article-149835.r20">[20]</xref><xref ref-type="bibr" rid="article-149835.r30">[30]</xref>&#x000a0;</p>
        <p>POCT, performed near patients, typically enhances patient satisfaction and experience by eliminating the need for sample transport, reducing turnaround time (TAT), and avoiding procedure delays. POCT enables patient counseling, prevents unnecessary treatment escalation, and provides rapid results outside the hospital setting, such as in outpatient testing, to avoid hospitalization or confirm viral illness, thereby reducing antibiotic use.</p>
        <p>POCT offers advantages in different test types. For example, fingerstick blood glucose measurements can replace venipuncture for serum testing, requiring less training and posing lower risks of complications and infection, thereby improving patient experience and safety.<xref ref-type="bibr" rid="article-149835.r31">[31]</xref> In specific patient populations like neonates or those prone to increased blood loss from phlebotomy, the smaller sample volume required for POCT is advantageous.</p>
        <p>POCT has some drawbacks, primarily related to the potential for less accurate results than traditional laboratory testing. This can be attributed to variable personnel training and control over pre-analytical, analytical, and post-analytical variables, which can be better managed in a laboratory setting. POCT can be more costly on a per-test basis compared to traditional laboratory testing, primarily due to the single-use nature of most POCT devices, which adds to the overall expenses.<xref ref-type="bibr" rid="article-149835.r32">[32]</xref>&#x000a0;Documentation challenges and potential errors in recording or documenting POCT results can occur due to varying personnel practices and workflow processes within a clinical setting.</p>
      </sec>
      <sec id="article-149835.s9" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>All facilities or sites in the US that conduct diagnostic testing or medical treatment using human specimens are subject to regulation under the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88).<xref ref-type="bibr" rid="article-149835.r33">[33]</xref> CLIA designates tests that are simple to perform and have a low risk of producing incorrect results as waived tests. Most point-of-care tests are waived; however, some are non-waived and are subcategorized as moderately complex tests. Waived tests are excluded from competency assessment requirements per the Centers for Medicare &#x00026; Medicaid (CMS), though various state and accrediting bodies may still keep this requirement in place. Non-waived tests are subject to specific quality standards, including proficiency testing, quality control (QC), and personnel requirements.</p>
        <p>The successful development of effective quality control for laboratory testing requires using verified controls to ensure that a POCT is functioning as expected and will yield accurate results.<xref ref-type="bibr" rid="article-149835.r34">[34]</xref>&#x000a0;QC&#x000a0;material contains the analytes of known concentrations. The frequency of quality control testing should be determined based on the complexity and risks associated with the test in question. For high-throughput devices, QC should be run at least once daily. New lots of reagents are tested with these controls before being used to run patient samples. Additionally, such controls allow for troubleshooting&#x000a0;among different individual tests and operators. The internal QC documentation, which includes the date and time of testing, lot number, and user identification, is essential for effective QC.</p>
        <p>Patient testing must be associated with the specific lot numbers for all products used for POCT, including the device, reagents, and sample collection materials. Many POCTs contain electronic records of such information, though historically, this information has been recorded in a logbook. Significant variables to ensure ongoing quality assurance include expiration dates for reagents, controls, and sample collection materials, proper storage and management of all materials involved in POCT, and proper establishment of acceptable ranges for test values.<xref ref-type="bibr" rid="article-149835.r34">[34]</xref></p>
        <p>Due to the decentralized nature of POCT, effective personnel management on an individual level is critical. Ideally, every person that runs POCT would be competent with the safe and accurate operation of each POCT. Many larger institutions implement electronic training modules and regularly track individual competency for POCT, in line with the requirements set by accreditation bodies such as CLIA.&#x000a0; Accreditation bodies, including CLIA, require&#x000a0;6 main competency elements: 1) direct observation of test operation, 2) monitoring of both recording and reporting of test results, 3) review of intermediate steps of POCT (test results, QC records), 4) direct observation of preventative maintenance and function check performance, 5) assessment of test performance using specimens previously analyzed, and 6) assessment of personnel problem-solving skills.<xref ref-type="bibr" rid="article-149835.r35">[35]</xref></p>
        <p>
<bold>Lab Safety</bold>
</p>
        <p>Lab safety is a critical component of effective POCT for the patient, the sample collector, and the person that runs the POCT. One unique aspect of POCT is that the same person often carries the collection and test execution. Because of this, care must be taken so that task overload and errors in collection, transport, and analysis do not occur. Contamination of a POCT can impact multiple patients and operators, especially if the POCT in question is frequently used. The proper use of personal protective equipment (PPE) and corresponding protocols are critical for the protection of personnel and the accuracy of testing.<xref ref-type="bibr" rid="article-149835.r36">[36]</xref></p>
        <p>The rules of universal precaution should be applied to POCT, and protective measures such as splash shields and biosafety cabinets should be employed based on manufacturer and government agency guidelines. Recommendations for competency elements in POCT vary depending on the type of test and the samples collected. For example, POC molecular testing for nasal swabs, such as in the case of COVID-19 testing, generally requires specific personal protective equipment (PPE) to prevent exposure to airborne pathogens during testing.<xref ref-type="bibr" rid="article-149835.r37">[37]</xref><xref ref-type="bibr" rid="article-149835.r38">[38]</xref></p>
        <p>Lab safety also applies to adequately disposing of samples and waste after completing POCT.<xref ref-type="bibr" rid="article-149835.r39">[39]</xref> All laws, regulations, and accreditation requirements for medical waste disposal must be followed. After sample collection via venipuncture, the needle must be covered; fingerstick lancets must be single-use. All needles&#x000a0;and lancets must be appropriately disposed of in a hazardous waste container designated for needles (a sharps container).</p>
        <p>Proper disposal of POCT swabs depends on local and facility waste disposal procedures. However, a general guideline is that swabs used for POCT that remove the sample from the swab (for example, POCT that wash or require swirling of the swab in fluid) do not require disposal in a designated biohazard receptacle.<xref ref-type="bibr" rid="article-149835.r8">[8]</xref> Swabs contaminated with biological material must be disposed of in a proper biohazard bag. Finally, when appropriate, the proper removal or covering of protected health information (PHI) must be considered on all samples and sample containers. This applies to both physical and electronic information.</p>
      </sec>
      <sec id="article-149835.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>POCT&#x000a0;occurs in a wide range of clinical settings, including inpatient, outpatient, and non-clinical settings, such as homes, airports, and cruise ships. The COVID-19 pandemic significantly increased the use of POCT, with billions of tests rapidly developed and distributed worldwide to help control the spread of the virus and facilitate the timely identification of infected individuals.</p>
        <p>Various healthcare professionals, including physicians, nurses, medical technologists, and trained personnel, perform point-of-care testing to obtain immediate results that inform and guide clinical patient management decisions. Due to the diverse range of healthcare professionals and workflows involved in POCT, providing adequate training, facilitating interprofessional communication, and establishing clear guidance to ensure accurate testing and effective relay of test results to the treatment team is crucial.</p>
        <p>Interprofessional committees dedicated to the implementation, execution, and continuous quality management of&#x000a0;POCT have been recommended as they play a crucial role in enhancing the quality of healthcare delivery within entire health systems. These committees promote collaboration, standardization, and effective oversight of POCT practices, ultimately benefiting patient care.<xref ref-type="bibr" rid="article-149835.r40">[40]</xref>&#x000a0;[Level&#x000a0;1] Various randomized clinical trials using POCT demonstrate improved patient outcomes compared to conventional laboratory testing.<xref ref-type="bibr" rid="article-149835.r41">[41]</xref><xref ref-type="bibr" rid="article-149835.r42">[42]</xref><xref ref-type="bibr" rid="article-149835.r43">[43]</xref>&#x000a0;[Level&#x000a0;1]</p>
        <p>One of the advantages of point-of-care testing (POCT) is the ability to update the patient's electronic medical record (EMR) with real-time test results. This enables the interprofessional team to access the most accurate and updated data, leading to a more comprehensive and functional clinical picture. As a result, healthcare professionals, such as pharmacists, can make more efficient and informed decisions regarding medication dosing, such as adjusting warfarin or aminoglycoside dosages, based on the patient's current status.</p>
        <p>Using POCT facilitates closer monitoring of a patient's condition by nurses. With real-time access to test results through the EMR, nurses can promptly detect any significant changes and alert the attending physician or appropriate healthcare professionals for clinical intervention. Interprofessional coordination and collaboration among physicians, advanced practice practitioners, specialists, pharmacists, lab technicians, and nurses are crucial in utilizing POCT effectively and ultimately enhancing patient outcomes. By working together, the healthcare team can make well-informed decisions and provide timely and targeted care based on the POCT results [Level 5]</p>
      </sec>
      <sec id="article-149835.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149835&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149835">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/149835/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=149835">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-149835.s12">
        <title>References</title>
        <ref id="article-149835.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Price</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Point of care testing.</article-title>
            <source>BMJ</source>
            <year>2001</year>
            <month>May</month>
            <day>26</day>
            <volume>322</volume>
            <issue>7297</issue>
            <fpage>1285</fpage>
            <page-range>1285-8</page-range>
            <pub-id pub-id-type="pmid">11375233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nichols</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Utilizing Point-of-Care Testing to Optimize Patient Care.</article-title>
            <source>EJIFCC</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-144</page-range>
            <pub-id pub-id-type="pmid">34421482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kost</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Ehrmeyer</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chernow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Zaloga</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shirey</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The laboratory-clinical interface: point-of-care testing.</article-title>
            <source>Chest</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>115</volume>
            <issue>4</issue>
            <fpage>1140</fpage>
            <page-range>1140-54</page-range>
            <pub-id pub-id-type="pmid">10208220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>Near Patient Testing Working Party</collab>
            <collab>General Haematology Task Force of BCSH</collab>
            <collab>Thrombosis and Haemostasis Task Force of BCSH</collab>
            <article-title>Guide-lines for near patient testing: haematology.</article-title>
            <source>Clin Lab Haematol</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-10</page-range>
            <pub-id pub-id-type="pmid">8697724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kost</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Jammal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Safwat</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Monitoring of ionized calcium during human hepatic transplantation. Critical values and their relevance to cardiac and hemodynamic management.</article-title>
            <source>Am J Clin Pathol</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-70</page-range>
            <pub-id pub-id-type="pmid">3524194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayden</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Luppa</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Point-of-care testing-new horizons for cross-sectional technologies and decentralized application strategies.</article-title>
            <source>Anal Bioanal Chem</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>414</volume>
            <issue>10</issue>
            <fpage>3161</fpage>
            <page-range>3161-3163</page-range>
            <pub-id pub-id-type="pmid">35274155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>MSF</given-names>
              </name>
              <name>
                <surname>McKeage</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>PMF</given-names>
              </name>
              <name>
                <surname>Taberner</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Minimally invasive capillary blood sampling methods.</article-title>
            <source>Expert Rev Med Devices</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-16</page-range>
            <pub-id pub-id-type="pmid">36694960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parihar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panda</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Parihar</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Microfluidics-Based Point-of-Care Testing (POCT) Devices in Dealing with Waves of COVID-19 Pandemic: The Emerging Solution.</article-title>
            <source>ACS Appl Bio Mater</source>
            <year>2022</year>
            <month>May</month>
            <day>16</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>2046</fpage>
            <page-range>2046-2068</page-range>
            <pub-id pub-id-type="pmid">35473316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St John</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Existing and Emerging Technologies for Point-of-Care Testing.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-67</page-range>
            <pub-id pub-id-type="pmid">25336761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagnana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caputo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giavarina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Overview on self-monitoring of blood glucose.</article-title>
            <source>Clin Chim Acta</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>402</volume>
            <issue>1-2</issue>
            <fpage>7</fpage>
            <page-range>7-13</page-range>
            <pub-id pub-id-type="pmid">19167374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giannuzzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ruggieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Felisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kubiak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demotes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ceci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonifazi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>PedCRIN tool for the biosamples management in pediatric clinical trials.</article-title>
            <source>Clin Transl Sci</source>
            <year>2023</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>797</fpage>
            <page-range>797-809</page-range>
            <pub-id pub-id-type="pmid">36757003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allardet-Servent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebsir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dubroca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fabrigoule</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jordana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Signouret</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castanier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soundaravelou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lepidi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delapierre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Penaranda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Halfon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Seghboyan</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Point-of-Care Versus Central Laboratory Measurements of Hemoglobin, Hematocrit, Glucose, Bicarbonate and Electrolytes: A Prospective Observational Study in Critically Ill Patients.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>e0169593</fpage>
            <pub-id pub-id-type="pmid">28072822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Intra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Giacobone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brivio</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hemolysis and blood gas analysis: it's time for a change!</article-title>
            <source>Scand J Clin Lab Invest</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-142</page-range>
            <pub-id pub-id-type="pmid">35152829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gauglitz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Point-of-care platforms.</article-title>
            <source>Annu Rev Anal Chem (Palo Alto Calif)</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>297</fpage>
            <page-range>297-315</page-range>
            <pub-id pub-id-type="pmid">25014344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moeller</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Engsig</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Bade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soerensen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Donolato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benfield</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring.</article-title>
            <source>Microbiol Spectr</source>
            <year>2022</year>
            <month>Apr</month>
            <day>27</day>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>e0039622</fpage>
            <pub-id pub-id-type="pmid">35357223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Reavis</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Quantitative, Point-of-Care Immunoassay Platform to Guide and Monitor Sickle Cell Disease Therapy.</article-title>
            <source>Anal Chem</source>
            <year>2016</year>
            <month>Aug</month>
            <day>16</day>
            <volume>88</volume>
            <issue>16</issue>
            <fpage>7904</fpage>
            <page-range>7904-9</page-range>
            <pub-id pub-id-type="pmid">27442043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azar</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests.</article-title>
            <source>J Clin Microbiol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">29695519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safiabadi Tali</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>LeBlanc</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sadiq</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Oyewunmi</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nikpour</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Armanfard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sagan</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jahanshahi-Anbuhi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2021</year>
            <month>Jun</month>
            <day>16</day>
            <volume>34</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">33980687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Tests for the diagnosis of Clostridium difficile infection: the next generation.</article-title>
            <source>Anaerobe</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>170</fpage>
            <page-range>170-4</page-range>
            <pub-id pub-id-type="pmid">21376826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>CES</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>JCC</given-names>
              </name>
              <name>
                <surname>Slhessarenko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scartezini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franca</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Colombini</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Berlitz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>AMO</given-names>
              </name>
              <name>
                <surname>Campana</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Faulhaber</surname>
                <given-names>ACL</given-names>
              </name>
              <name>
                <surname>Galoro</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shcolnik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>MDV</given-names>
              </name>
              <name>
                <surname>Cesar</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Sumita</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Mendes</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Faulhaber</surname>
                <given-names>MHW</given-names>
              </name>
              <name>
                <surname>Pinho</surname>
                <given-names>JRR</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Batista</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Khawali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pariz</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Andriolo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Point-of-Care Testing: General Aspects.</article-title>
            <source>Clin Lab</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">29479878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Augustine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narayan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Riordan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luong</surname>
                <given-names>JHT</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Point-of-Care PCR Assays for COVID-19 Detection.</article-title>
            <source>Biosensors (Basel)</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">34062874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazmierczak</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Morosyuk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Preanalytical Point-of-Care Testing Errors and Their Impact on Productivity in the Emergency Department in the&#x000a0;United States.</article-title>
            <source>J Appl Lab Med</source>
            <year>2022</year>
            <month>May</month>
            <day>04</day>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>650</fpage>
            <page-range>650-660</page-range>
            <pub-id pub-id-type="pmid">35015866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Hara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Kazmierczak</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>The Impact of Undetected In Vitro Hemolysis or Sample Contamination on Patient Care and Outcomes in Point-of-Care Testing: A Retrospective Study.</article-title>
            <source>J Appl Lab Med</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>332</fpage>
            <page-range>332-341</page-range>
            <pub-id pub-id-type="pmid">32445387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haleyur Giri Setty</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lathrop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hewlett</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Biotin Interference in Point of Care HIV Immunoassay.</article-title>
            <source>Biores Open Access</source>
            <year>2020</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>243</fpage>
            <page-range>243-246</page-range>
            <pub-id pub-id-type="pmid">33269113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schleis</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Interference of maltose, icodextrin, galactose, or xylose with some blood glucose monitoring systems.</article-title>
            <source>Pharmacotherapy</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>1313</fpage>
            <page-range>1313-21</page-range>
            <pub-id pub-id-type="pmid">17723085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cadamuro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Danese</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montagnana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Meyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvagno</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Simundic</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Internal quality assurance of HIL indices on Roche Cobas c702.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>e0200088</fpage>
            <pub-id pub-id-type="pmid">29979722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krasowski</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Educational Case: Hemolysis and Lipemia Interference With Laboratory Testing.</article-title>
            <source>Acad Pathol</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>6</volume>
            <fpage>2374289519888754</fpage>
            <pub-id pub-id-type="pmid">31803827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>LaValley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bagley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Point of care blood glucose devices in the hospital setting.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>290</fpage>
            <page-range>290-299</page-range>
            <pub-id pub-id-type="pmid">36734399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schifman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Reliability of point-of-care capillary blood glucose measurements in the critical value range.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>138</volume>
            <issue>7</issue>
            <fpage>962</fpage>
            <page-range>962-6</page-range>
            <pub-id pub-id-type="pmid">24978924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goble</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rocafort</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Point-of-Care Testing.</article-title>
            <source>J Pharm Pract</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>229</fpage>
            <page-range>229-237</page-range>
            <pub-id pub-id-type="pmid">26092752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trueblood</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Feasibility of Portable Fingerstick Cholinesterase Testing in Adolescents in South Texas.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>10</volume>
            <fpage>2150132719838716</fpage>
            <pub-id pub-id-type="pmid">30929548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilir</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kruger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Munakata</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karichu</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Sickler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>US cost-effectiveness and budget impact of point-of-care NAAT for streptococcus.</article-title>
            <source>Am J Manag Care</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>e157</fpage>
            <page-range>e157-e163</page-range>
            <pub-id pub-id-type="pmid">34002967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbin</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Klepser</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Klepser</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pharmacy-Based Infectious Disease Management Programs Incorporating CLIA-Waived Point-of-Care Tests.</article-title>
            <source>J Clin Microbiol</source>
            <year>2020</year>
            <month>Apr</month>
            <day>23</day>
            <volume>58</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32075903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Shakeel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hooda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jafri</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Best Practices in the Implementation of a Point of Care Testing Program: Experience From a Tertiary Care Hospital in a Developing Country.</article-title>
            <source>EJIFCC</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>288</fpage>
            <page-range>288-302</page-range>
            <pub-id pub-id-type="pmid">31695586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Astles</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Stang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alspach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bosse</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>CLIA requirements for proficiency testing: the basics for laboratory professionals.</article-title>
            <source>MLO Med Lab Obs</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>9</issue>
            <fpage>8</fpage>
            <page-range>8-10, 12, 14-5; quiz 16</page-range>
            <pub-id pub-id-type="pmid">24147329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nogueras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marinsalta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roussell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Notario</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Importance of hand germ contamination in health-care workers as possible carriers of nosocomial infections.</article-title>
            <source>Rev Inst Med Trop Sao Paulo</source>
            <year>2001</year>
            <season>May-Jun</season>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>149</fpage>
            <page-range>149-52</page-range>
            <pub-id pub-id-type="pmid">11452323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ndateva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schwandt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saewyc</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tobias</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ranger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Participants' experience in using a point of Care Rapid Antigen Test (RAT) for SARS-CoV-2.</article-title>
            <source>Ann Fam Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>20</volume>
            <issue>20 Suppl 1</issue>
            <pub-id pub-id-type="pmid">36706377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burnes</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sheldrake</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faheem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Christie-Holmes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kandel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frankland</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gubbay</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Corbeil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kozak</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>One swab, two tests: Validation of dual SARS-CoV-2 testing on the Abbott ID NOW&#x02122;.</article-title>
            <source>J Clin Virol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>141</volume>
            <fpage>104896</fpage>
            <pub-id pub-id-type="pmid">34174710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ongaro</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ndlovu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sollier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Otieno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ondoa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Street</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kersaudy-Kerhoas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Engineering a sustainable future for point-of-care diagnostics and single-use microfluidic devices.</article-title>
            <source>Lab Chip</source>
            <year>2022</year>
            <month>Aug</month>
            <day>23</day>
            <volume>22</volume>
            <issue>17</issue>
            <fpage>3122</fpage>
            <page-range>3122-3137</page-range>
            <pub-id pub-id-type="pmid">35899603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobs</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hinson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tolnai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Implementation, management and continuous quality improvement of point-of-care testing in an academic health care setting.</article-title>
            <source>Clin Chim Acta</source>
            <year>2001</year>
            <month>May</month>
            <volume>307</volume>
            <issue>1-2</issue>
            <fpage>49</fpage>
            <page-range>49-59</page-range>
            <pub-id pub-id-type="pmid">11369337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattila</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paalanne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Honkila</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pokka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tapiainen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effect of Point-of-Care Testing for Respiratory Pathogens on Antibiotic Use in Children: A Randomized Clinical Trial.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>e2216162</fpage>
            <pub-id pub-id-type="pmid">35679047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chibwesha</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mollan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Shibemba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Lusaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mbewe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Allmon</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Lungu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>HML</given-names>
              </name>
              <name>
                <surname>Mweni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mwape</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kankasa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Stringer</surname>
                <given-names>JSA</given-names>
              </name>
            </person-group>
            <article-title>A Randomized Trial of Point-of-Care Early Infant Human Immunodeficiency Virus (HIV) Diagnosis in Zambia.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Aug</month>
            <day>25</day>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <page-range>260-268</page-range>
            <pub-id pub-id-type="pmid">34718462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149835.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lax</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pesonen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hiippala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schramko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lassila</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raivio</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery-Results of a Randomized Controlled Trial.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>2362</fpage>
            <page-range>2362-2368</page-range>
            <pub-id pub-id-type="pmid">32127275</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
